The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Although the early growth response-2 (Egr-2, alias Krox20) protein shows structural and functional similarities to Egr-1, these two related early-immediate transcription factors are nonredundant. Egr-2 plays essential roles in peripheral nerve myelination, adipogenesis, and immune tolerance; however, its regulation and role in tissue repair and fibrosis remain poorly understood. We show herein that transforming growth factor (TGF)-β induced a Smad3-dependent sustained stimulation of Egr2 gene expression in normal fibroblasts. Overexpression of Egr-2 was sufficient to stimulate collagen gene expression and myofibroblast differentiation, whereas these profibrotic TGF-β responses were attenuated in Egr-2-depleted fibroblasts. Genomewide transcriptional profiling revealed that multiple genes associated with tissue remodeling and wound healing were up-regulated by Egr-2, but the Egr-2-regulated gene expression profile overlapped only partially with the Egr-1-regulated gene profile. Levels of Egr-2 were elevated in lesional tissue from mice with bleomycin-induced scleroderma. Moreover, elevated Egr-2 was noted in biopsy specimens of skin and lung from patients with systemic sclerosis. These results provide the first evidence that Egr-2 is a functionally distinct transcription factor that is both necessary and sufficient for TGF-β-induced profibrotic responses and is aberrantly expressed in lesional tissue in systemic sclerosis and in a murine model of scleroderma. Together, these findings suggest that Egr-2 plays an important nonredundant role in the pathogenesis of fibrosis. Targeting Egr-2 might represent a novel therapeutic strategy to control fibrosis.

[1]  J. Varga,et al.  The Early-Immediate Gene EGR-1 Is Induced by Transforming Growth Factor-β and Mediates Stimulation of Collagen Gene Expression* , 2006, Journal of Biological Chemistry.

[2]  Giuseppe Cibelli,et al.  Regulation of life and death by the zinc finger transcription factor Egr‐1 , 2002, Journal of cellular physiology.

[3]  J. Milbrandt,et al.  Luteinizing Hormone Deficiency and Female Infertility in Mice Lacking the Transcription Factor NGFI-A (Egr-1) , 1996, Science.

[4]  J. Powell,et al.  Opposing regulation of T cell function by Egr‐1/NAB2 and Egr‐2/Egr‐3 , 2008, European journal of immunology.

[5]  J. Varga,et al.  Scleroderma: from cell and molecular mechanisms to disease models. , 2005, Trends in immunology.

[6]  S. O’Rahilly,et al.  The transcription factors Egr1 and Egr2 have opposing influences on adipocyte differentiation , 2009, Cell Death and Differentiation.

[7]  W. Tourtellotte,et al.  Cell Injury , Repair , Aging and Apoptosis Essential Roles for Early Growth Response Transcription Factor Egr-1 in Tissue Fibrosis and Wound Healing , 2010 .

[8]  Traci Galbaugh,et al.  Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells. , 2010, Journal of molecular endocrinology.

[9]  Toshiyuki Yamamoto,et al.  Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. , 2003, The Journal of investigative dermatology.

[10]  M. Cramer,et al.  The human transcriptional repressor protein NAB1: expression and biological activity. , 2000, Biochimica et biophysica acta.

[11]  C. Clevenger,et al.  Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. , 2009, Endocrinology.

[12]  Minghua Wu,et al.  Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. , 2009, The American journal of pathology.

[13]  T. Murphy,et al.  Synaptic Regulation of Immediate Early Gene Expression in Primary Cultures of Cortical Neurons , 1991, Journal of neurochemistry.

[14]  J. Allison,et al.  Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections , 2009, Immunological reviews.

[15]  C. Wijmenga,et al.  Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis* , 2003, Journal of Biological Chemistry.

[16]  L. Glimcher,et al.  Sequential involvement of NFAT and Egr transcription factors in FasL regulation. , 2000, Immunity.

[17]  J. Varga,et al.  Molecular pathways as novel therapeutic targets in systemic sclerosis , 2007, Current opinion in rheumatology.

[18]  W. Leonard,et al.  The immediate-early gene product Egr-1 regulates the human interleukin-2 receptor beta-chain promoter through noncanonical Egr and Sp1 binding sites , 1997, Molecular and cellular biology.

[19]  B. Frenkel,et al.  Opposing effects of glucocorticoids and Wnt signaling on Krox20 and mineral deposition in osteoblast cultures , 2008, Journal of cellular biochemistry.

[20]  Minghua Wu,et al.  In perspective: Murine models of scleroderma , 2008, Current rheumatology reports.

[21]  E. Mozes,et al.  A Peptide That Ameliorates Lupus Up-Regulates the Diminished Expression of Early Growth Response Factors 2 and 31 , 2008, The Journal of Immunology.

[22]  Simon M. Lin,et al.  Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. , 2009, The American journal of pathology.

[23]  W. Huber,et al.  Model-based variance-stabilizing transformation for Illumina microarray data , 2008, Nucleic acids research.

[24]  G. Crabtree,et al.  The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells , 2009, Nature Immunology.

[25]  C. Clevenger,et al.  Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter , 2008, BMC biotechnology.

[26]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[27]  V. Sukhatme,et al.  A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. , 1987, Oncogene research.

[28]  S. Jimenez,et al.  Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis , 2004, Annals of Internal Medicine.

[29]  R. Schmidt,et al.  Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Linda J. Sandell,et al.  Egr-1 Mediates Transcriptional Repression of COL2A1Promoter Activity by Interleukin-1β* , 2003, The Journal of Biological Chemistry.

[31]  Paul Martin,et al.  Immediate early genes krox‐24 and krox‐20 are rapidly up‐regulated after wounding in the embryonic and adult mouse , 2002, Developmental dynamics : an official publication of the American Association of Anatomists.

[32]  C. Heldin,et al.  Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. , 2009, Current opinion in cell biology.

[33]  Alistair L. J. Symonds,et al.  Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease , 2008, The Journal of experimental medicine.

[34]  Minghua Wu,et al.  Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. , 2008, The American journal of pathology.

[35]  J. Varga,et al.  Animal models of scleroderma. , 2004, Methods in molecular medicine.

[36]  H. Ihn,et al.  Transcriptional Regulation of the Human α2(I) Collagen Gene , 1996, The Journal of Biological Chemistry.

[37]  Warren A Kibbe,et al.  nuID: a universal naming scheme of oligonucleotides for Illumina, Affymetrix, and other microarrays , 2007, Biology Direct.

[38]  D. Brenner,et al.  Fibrosis research : methods and protocols , 2005 .

[39]  D. Foster,et al.  The 5'-flanking region of the mouse vascular smooth muscle alpha-actin gene contains evolutionarily conserved sequence motifs within a functional promoter. , 1990, The Journal of biological chemistry.

[40]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[41]  Jeanne Kowalski,et al.  Egr-2 and Egr-3 are negative regulators of T cell activation , 2005, Nature Immunology.

[42]  Y. Okada,et al.  Regulatory polymorphisms in EGR2 are associated with susceptibility to systemic lupus erythematosus. , 2010, Human molecular genetics.

[43]  C. Feghali-Bostwick,et al.  Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. , 2008, The American journal of pathology.

[44]  I. Graef,et al.  Calcineurin/NFAT Signaling Is Required for Neuregulin-Regulated Schwann Cell Differentiation , 2009, Science.

[45]  G. Merlo,et al.  Differential regulation of the zinc finger genes Krox‐20 and Krox‐24 (Egr‐1) suggests antagonistic roles in Schwann cells , 1997, Journal of neuroscience research.

[46]  J. Rowley,et al.  Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with "zinc-binding finger" structure. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Nathans,et al.  DNA binding site of the growth factor-inducible protein Zif268. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Pasche,et al.  Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis , 2008, Current opinion in rheumatology.

[49]  M. A. Basson,et al.  Early Growth Response (Egr)-1 Gene Induction in the Thymus in Response to TCR Ligation During Early Steps in Positive Selection Is Not Required for CD8 Lineage Commitment1 , 2000, The Journal of Immunology.

[50]  J. Baraban,et al.  The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience , 1999, Trends in Neurosciences.

[51]  S. Jimenez,et al.  Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. , 2008, Arthritis and rheumatism.